Clinical Trial Update: Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial assessing pembrolizumab monotherapy in muscle-invasive bladder cancer to study mechanisms of action.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED